TABLE 1.
Susceptibility of HIV-1 and HIV-2 isolates to cabotegravir in single-cycle infections of MAGIC-5A cells
| Isolate by HIV type | Group/subtype | EC50 (nM)a for: |
|
|---|---|---|---|
| Cabotegravirb | Efavirenzc | ||
| HIV-1 | |||
| 92UG029 | M/A | 2.0 ± 0.43 | 2.9 ± 0.35 |
| NL4-3 | M/B | 1.5 ± 0.31 | 2.2 ± 0.46 |
| LAI | M/B | 1.4 ± 0.45 | 1.7 ± 0.073 |
| MJ4 | M/C | 1.3 ± 0.061 | 1.4 ± 0.16 |
| 92UG001 | M/D | 2.2 ± 1.3 | 2.0 ± 0.21 |
| MVP5180-91 | O | 2.0 ± 0.11 | 54 ± 6.5 |
| HIV-2 | |||
| ROD9 | A | 1.6 ± 0.45 | >1,000 |
| 7924A | A | 1.0 ± 0.15 | >1,000 |
| MVP15132 | A | 2.5 ± 1.2 | >1,000 |
| 60415K | A | 2.7 ± 0.70 | >1,000 |
| CBL-20 | A | 0.92 ± 0.048 | >1,000 |
| CBL-23 | A | 2.1 ± 0.79 | >1,000 |
| CDC77618 | A | 2.3 ± 0.81 | >1,000 |
| ST | A | 1.6 ± 0.30 | >1,000 |
| CDC310072 | B | 1.0 ± 0.23 | >1,000 |
| CDC310319 | B | 4.0 ± 0.84 | >1,000 |
| EHO | B | 4.1 ± 1.4 | >1,000 |
| DIL | B | 2.5 ± 0.33 | >1,000 |
| COU | B | 2.3 ± 0.46 | >1,000 |
| BER | B | 2.7 ± 0.82 | >1,000 |
| 7312A | CRF01_ABd | 1.6 ± 0.46 | >1,000 |
EC50, 50% effective concentration (mean ± SD).
All EC50s for cabotegravir were calculated from three or more independent assay runs. EC50s for NL4-3 and ROD9 were obtained using cabotegravir from GlaxoSmithKline, Inc., and Selleck Chemicals, Inc. (see also Table S1 in the supplemental material). The remaining isolates listed above were tested against cabotegravir from Selleck Chemicals.
The NNRTI efavirenz serves as a non-INI control. EC50s for efavirenz are the results of 3 determinations for each HIV-1 isolate and ≥2 determinations for each HIV-2 isolate.
Intergroup (A/B) recombinant. The integrase-encoding sequence of HIV-27312A is monophyletic with that of other isolates belonging to HIV-2 group B (72).